课题组研究方向：

1.纳米药物、药物新剂型和新技术等

2.具有良好成药性纳米药物制剂的基础研究与开发，包括高载药量前药自组装体系、主动载药脂质体、高载药量脂肪乳等

3.转运体介导抗癌前药的设计与开发

4.生物药剂学和药物动力学

5.药物分析新技术的应用和药品质量标准研究、基于代谢酶和转运体相关的前药设计与评价、难溶性药物的增溶技术及体内外评价

近年来课题组发表代表性论文：

1.Luo C, Sun J*, Liu D, Sun B, Miao L, Musetti S, Li J, Han X, Du Y, Li L, Huang L, He Z*. Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy. Nano Lett. 2016;16(9):5401-8. (IF=13.779)

2.Yongjun Wang, et al. Disulfide Bond Bridge Inse rtion Turns Hydrophobic Anticancer Prodrugs into Self-Assembled Nanomedicines. Nano Letters. 2014;14:5577-5583.（IF=13.592）

3.Luo C, SunJ*, Liu D, Sun B, Miao L, Musetti S, Li J, Han X, Du Y, Li L, Huang L, HeZ*.Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by SingleThioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy, NanoLetter , DOI: 10.1021/acs.nanolett.6b01632. (IF=13.78)

4.ZhenjieWang, Xiao Kuang, Jia Shi, Weiling Guo and Hongzhuo Liu*, Targeted delivery ofgeranylgeranylacetone to mitochondria by triphenylphosphonium modifiednanoparticles: a promising strategy to prevent aminoglycoside-induced hearingloss, Biomater Sci, 2017, 5(9):1800-1809.（IF 4.21）

5.Increased dissolution rate and oral bioavailability of hydrophobic drug glyburide tablets produced using supercritical CO₂ silica dispersion technology，European Journal of Pharmaceutics and Biopharmaceutics，2014，（IF=4.245）